Patent Reform

By Don J. Pelto and Andrew Keith

The Senate passed their version of a Patent Reform Bill (Senate Bill No. S. 23), on March 8, 2011 by a wide 95-5 margin. The bill makes significant changes, most notably including a first-inventor-to-file system, and an enhanced post-grant review procedures that will be conducted within the USPTO. There are 26 sections to the Senate bill. Some key features of the Senate Bill include:

  1. A first-inventor-to-file system and limitation of the one year grace period (Sec. 2);
  2. A Post-grant review proceeding (Sec. 5);
  3. New inter partes review proceeding (Sec. 5a);
  4. Preissuance submission by third parties (Sec. 7);
  5. USPTO fee-setting authority and USPTO funding (Secs. 9 and 10);
  6. A supplemental examination proceeding (Sec. 11);
  7. Elimination of the best mode defense (Sec. 15.); 
  8. A transitional post-grant review of covered business method patents(Sec. 18); and
  9. A change to the False marking Statute (Sec. 2).
Continue Reading...

Adjusting the Inequitable Conduct Doctrine: Federal Circuit Hears Oral Arguments En Banc in Therasense

By Gray M. Buccigross

On November 9, 2010, the Federal Circuit, sitting en banc, heard oral arguments in Therasense, Inc. v. Becton, Dickinson & Co., regarding the legal tests to be applied in determining whether a patent is unenforceable due to inequitable conduct. This has been a controversial issue over the last several years among practitioners, Federal Circuit judges, and industry groups, particularly Big Pharma. This article assumes some familiarity with the case and the issues. However, for background information on both, please click here.

 

Continue Reading...

Therasense Opinions And The Doctrine Of Inequitable Conduct

By Gray M. Buccigross

I. BRIEF OVERVIEW OF THE DOCTRINE

Each person associated with the prosecution of a patent application has a duty of candor and good faith in dealing with the Patent and Trademark Office (“PTO”). Under the doctrine of inequitable conduct, a patent may be rendered unenforceable where that duty is breached, and the person intended to deceive or mislead the PTO.
 

Continue Reading...

District Court Holds Gene Sequences Not Patentable Subject Matter

By Jennifer Trusso

On March 29, 2010, in the highly publicized and closely watched case of Association for Molecular Pathology, et al v. U. S. Patent and Trademark Office, et al. (real parties in interest patent holders Myriad Genetics and the University of Utah Research Foundation), the District Court in the Southern District of New York granted summary judgment in favor of Plaintiffs and held that 15 claims in Myriad’s 7 patents relating to human BRCA1 and BRCA2 genes (Breast Cancer Susceptibility genes 1 and 2) (collectively “BRCA1/2”) are invalid because they claim non-patentable subject matter.
 

Continue Reading...